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Abstract: The rates of opioid prescription and use have 
continued to increase over the last few decades. In turn, 
a greater number of patients suffer from opioid 
tolerance. Treatment of acute pain is a clinical challenge 
for these patients. Acute pain can arise from common 
occurrences like surgical pain and pain resulting from 
the injury. P-glycoprotein (p-gp) is a transporter at the 
blood-brain barrier (BBB) associated with a decrease in 
the analgesic efficacy of morphine. Peripheral 
inflammatory pain (PIP) is a pain state known to cause a 
change in p-gp trafficking at the BBB. P-gp traffics 
from the nucleus to the luminal surface of endothelial 
cells making up the BBB. This surface where 
circulating blood interfaces with the endothelial cell is 
where p-gp will efflux morphine back into circulation. 
Osmotic minipumps were used as a long-term delivery 
method in this model of opioid tolerance in female rats. 
PIP induced p-gp trafficking away from nuclear stores 
showed a 2-fold increase when animals were exposed to 
opioids for 6 days. This observation presents a possible 
relationship between p-gp trafficking and the challenges 
of treating post-surgical pain in opioid tolerant patients. 
This could reveal potential strategies for improving pain 
management in these patients. 
 Keywords: peripheral inflammatory pain, p-
glycoprotein, chronic opioid exposure 
INTRODUCTION  
Pain management is  an important part of recovery 
for patients following surgery. Poor pain 
management can lead to slower recovery, an 
increased probability of readmission, increased 
cost of care and decreased patient satisfaction (1). 
Intravenous opioid analgesics, such as morphine, 
are currently the standard of care for post-surgical 
pain. Opioids are the most effective therapy for 
reducing reported pain in most patients. In a 
hospital setting, opioids are most commonly 
administered by nursing staff or through a patient-
controlled analgesia (PCA) system (2). A problem 
arises when a patient with a previous history of 
chronic opioid use is treated for post-surgical pain. 
It has been reported that when these patients 
receive opioid analgesics following surgery, the 
treatment is less effective and some patients feel 
more pain (3). The tolerance associated with long-
term use of opioids leads reduced efficacy. 
Opioid-induced hyperalgesia (OIH) is a related 
pathology in which patients become more 
sensitive to stimuli following long-term exposure 
to opioids (4). These two phenomena are 
examples of the clinical challenges associated 
with long-term opioid therapies. The ATP-binding 
cassette protein P-glycoprotein (p-gp) at the 
blood-brain barrier (BBB) is thought to play a role 
in decreased opioid efficacy. At the BBB, p-gp 
acts as an efflux protein transporting a variety of 
compounds back into circulating blood before 
these compounds can enter the brain. Rats 
chronically exposed to morphine, a substrate of p-
gp, have a 4-fold decrease in morphine entering 
the CNS as well as a 2-fold increase in expression 
of the protein in sampled whole brain tissue (5). 
Pain has also been shown to be sufficient to 
decrease the antinociceptive efficacy of morphine 
(6). A combinatory effect of these two 
observations may explain a role of the BBB in the 
challenge of treating post-surgical pain in long-
term opioid-treated patients. 
The Problem of Pain 
In his famous novel 1984, George Orwell 
describes ―Of pain you could wish only one thing: 
that it should stop. Nothing in the world was so 
bad as physical pain. In the face of pain there are 
no heroes.‖ 
Even with this negative association, pain serves as 
an invaluable tool for survival. Acute pain acts as 
a signal of noxious stimuli as well as reinforcing 
behaviors that avoid these stimuli. Pain also acts 
as a clue of internal injuries such as muscular 
damage or broken bones. Changes can occur in 
pain pathways resulting in an altered, chronic 
state. As a protective adaptation, this can alter 
behavior to protect the site of an injury allowing 
the injury to heal without further harm. In some 
cases, this chronic pain will persist at the site of an 
injury well past the time protective pain is 
beneficial to healing. 
In the central nervous system, nociceptors project 
to differing laminae of the dorsal horn of the 
spinal cord depending on the type of nociceptive 
fiber. A variety of signaling molecules act at the 
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synapses between the central terminal of the 
nociceptors and the laminae of the spinal cord (8). 
Neurons within these laminae are responsible for 
transmitting the nociceptive signal through the 
spinal cord in a contralateral manner to the 
thalamus of the brain. From here, signals are sent 
to the somatosensory cortex and limbic system. 
While this process is short-lived for acute pain, 
persistent or chronic pain can arise when there is 
an anomaly in this system. The anomaly can be 
caused by over sensitization of nociceptors or 
because of spontaneous firing. Pharmacological 
modification of this pathway can be used as a 
strategy to reduce or eliminate pain. 
Opioids 
Opioids are a class of drugs with several useful 
effects including cough suppression and gastric 
slowing but are most commonly known and 
prescribed for analgesic effects. These drugs, as 
well as a few endogenous opioids, work at the 
class of receptors known as opioid receptors. 
There are three subtypes of opioid receptors: 
kappa, delta and, mu. Mu opioid receptors are 
believed to be the most important to the analgesic 
effects of opioids. All opioid receptors are 
inhibitory G protein-coupled receptors. The 
endogenous agonists for these receptors are 
dynorphins, enkephalins and endorphins, 
respectively (9). Opioid analgesics can be 
administered through suppository or intrathecally, 
but are most commonly administered 
intravenously or orally. More lipophilic opioids 
can also be administered transdermally. As 
described by Yaksh and Wallace in Goodman and 
Gilman's: The Pharmacological Basis of 
Therapeutics, oral opioids are subject to the first 
pass effect as well as poor absorption due to ion 
trapping and have a bioavailability of about 25% 
(10). Yaksh and Wallace continue to describe 
intravenous administration of opioids results in 
prompt action. The speed of action is affected by 
the lipophilicity of the compound which 
contributes to differences in the speed at which the 
compound can cross the BBB and enter the central 
nervous system (CNS). Morphine does not persist 
in tissue and is found in trace quantities 24 hours 
after the last administered dose. Metabolism of 
morphine relies on conjugation with glucuronic 
acid producing two metabolites, morphine-6-
glucuronide (M6G) and morphine-3-glucuronide 
(M3G). M6G has an analgesic effect. It is twice as 
potent as morphine, and is thought to make up a 
significant portion of morphine’s analgesic effect 
in patients treated with long-term opioid therapy 
(11). The more prevalent metabolite, M3G, is 
known to have neuroexcitatory effects (12). M3G 
is also the primary form excreted from the body 
(10). While almost no unmodified morphine is 
excreted, morphine’s metabolites are excreted 
through the kidneys. 
As previously mentioned, in addition to the pain 
relieving effects of opiates, opioid analgesics can 
elicit strong feelings of euphoria. Because of this 
and severe withdrawal symptoms, addiction and 
abuse are problems for many individuals including 
both those who began as therapeutic users and 
exclusively recreational users (24). Opioid 
addiction, also known as opioid use disorder, is a 
psychological condition defined as ―compulsive, 
prolonged self-administration of opioid substances 
that are used for no legitimate medical purpose or, 
if another medical condition is present that 
requires opioid treatment, that are used in doses 
greatly in excess of the amount needed for that 
medical condition,‖ (25). Both those using opioids 
recreationally for euphoric effects and those who 
begin using them for medical conditions are at risk 
of addiction. Addiction will take over the 
individual’s life, and most of the affected 
individual’s resources will be spent attempting to 
obtain more of the drug. Addiction and abuse have 
been a problem associated with opiates ever since 
man first discovered them. 
An Epidemic 
Today, the abuse of opioids has been described as 
an epidemic in the United States. The use of 
opioids affects all demographics of Americans and 
continues to become more common. On average, 
3,900 individuals begin the non-medical use of 
prescription opioids, and 580 individuals begin 
heroin use every day (39). A study revealed 
emergency room visits caused by non-medical 
opioid use have doubled from 2004 to 2011, 
totalling a staggering 488,000 visits in 2011 alone 
(40). A study by Rudd et al. examining drug 
overdose deaths related to opioids, including both 
opioid pain relievers and heroin, demonstrated an 
increase in deaths of 200% between 2000 and 
2014 (41). The study went on to demonstrate the 
increase in opioid-related deaths was much higher 
than the increase in overdose related deaths 
including all causes which were 137%. This trend 
is still continuing currently, with an increase of 
14% of opioid-related deaths from 2013 to 2014 
compared to a 6.5% increase in overall overdose-
related deaths. The increase in deaths was 
significant for both sexes, people 25-44 and those 
55 and older and in the Northeastern, Southern 
and Midwestern regions of the United States. 
Deaths related to natural and semi-synthetic 
opioids, heroin and synthetic opioids, excluding 
methadone, have all had significant increases. 
Synthetic opioids, excluding methadone, had the 
greatest increase in overdose related deaths with a 
90% increase between 2013 and 2014. Methadone 
has not had an overall increase in overdose related 
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deaths between 2013 and 2014. Increasing opioid 
overdose related to opioids prescribed as pills 
meant for pain management is not surprising 
given that this is how a majority of modern 
recreational opioid users begin their experience 
with opioids (44). Monitoring of opioid 
consumption of patients that receive them by 
prescription may not be sufficient to prevent 
abuse. Misuse of prescription refills and ―doctor 
shopping,‖ a situation where an individual seeking 
opioids may go to several different doctors to 
receive multiple prescriptions for the drugs, are 
common problems associated with prescribed 
opioids (32). Prescription opioids can also be sold 
or shared by patients with a legitimate 
prescription. The sale of opioids through the 
internet is also a uniquely modern challenge for 
monitoring the consumption of opioid analgesics 
(44). 
From 2010 to 2013, individuals who had used an 
opioid in the past month began to use only 
prescription opioids less and used a combination 
of opioids and heroin more, according to a self-
administered survey of diagnosed opioid abusers 
(54). A possible contributing factor to increasing 
heroin use is the increasing availability of heroin 
in the United States. A federal report states that 
much of the heroin in the United States comes 
from Mexico and production of the drug in that 
country continues to rise (55). This report also 
states heroin is less expensive than prescription 
opioids on the streets. The estimated cost of a 10 
mg dose of oxycodone is approximately $10 while 
it is estimated 50 mg of 50% pure heroin is around 
the same price. Heroin use may also be favorable 
because of the increased potency of the drug 
compared to morphine due to a larger amount 
being able to cross the BBB compared to 
morphine (56). 
The Blood-Brain Barrier 
The BBB is a barrier formed by the endothelial 
cells surrounding the lumen of the brain 
microvasculature. Adjacent endothelial cells 
attach to themselves and each other with tight 
junctions. These junctions, as described by 
Campbell, are made up of several transmembrane 
proteins and are responsible for a large part of the 
impermeability of the barrier (57). Several forms 
of the claudin protein are expressed at the BBB 
and seem to be very important for the formation of 
these tight junctions. Adherens junctions are 
another type of cell junction at the BBB and allow 
the endothelial cells to link to themselves. Thes e 
junctions help set up cell polarity and are formed 
with cadherin proteins. Pericytes surround the 
endothelial cells. Pericytes belong to the vascular 
smooth muscle cell family and provide structural 
support for the BBB and play an important role in 
the establishment of the BBB (58). Both pericytes 
and the endothelial cells are found in the basement 
membrane which contains many proteins that play 
a direct role in the activity of endothelial cells. 
Disruption of this basement membrane in certain 
disease states is very closely related to disruption 
in the activity of the BBB (59). Astrocytes are 
important to the maintenance of the BBB and co-
culture of endothelial cells with astrocytes 
improves BBB characteristics in vitro (58,60). In 
vivo studies in which loss of astrocytes at a 
particular location have confirmed astrocytes play 
an important role in the integrity of the BBB (59). 
The ability of the BBB to act as a selectively 
permeable barrier is heavily reliant on transport 
proteins. Because the tight junctions of the BBB 
are mostly impermeable, transport proteins are 
essential for the movement of nutrients into and 
keeping potentially dangerous compounds out of 
the brain. Glucose, essential for brain function, 
requires a transporter to cross the barrier. The 
GLUT1 transporter is responsible for glucose 
transport and allows glucose to travel into the 
brain along its concentration gradient (61). Some 
transporters act to export compounds from the 
BBB, most notably the ATP-Binding Cassette 
(ABC) proteins (62). Of these, p-gp, also known 
as multiple drug resistant protein 1 (Mdr1), plays 
a major role in the mechanism by which these 
potentially dangerous compounds are removed 
(63,64). This protein is important for the 
management of certain disease states. In a study of 
Alzheimer disease, p-gp was shown to mediate the 
clearance of amyloid-β from the brain (65). P-gp 
is of particular interest because it has a wide range 
of substrates, and a poorly understood system of 
regulators. P-gp is regulated both by the level of 
expression and through post-translational 
regulation through trafficking. Breast cancer 
resistance protein (BCRP) is another important 
efflux protein at the BBB (66,67). BCRP may also 
have a higher importance related to xenobiotic 
regulation in the BBB than p-gp (68). 
pioids and the Blood-Brain Barrier 
Morphine is the international standard for opioid 
analgesics. As previously discussed, morphine is 
metabolized into M3G and M6G via 
glucuronidation, leading to blood concentrations 
of these metabolites several times higher than that 
of the parent compound. Morphine can be 
metabolized to M3G and M6G in the brain 
directly (87). Morphine and M3G, the metabolite 
with no analgesic activity, are strong substrates for 
p-gp, and thus have poor penetration into the brain 
(88). M6G, the metabolite with higher analgesic 
potency than the parent compound, has not been 
demonstrated to be a p-gp substrate, however still 
does not penetrate the BBB (89). Genetic 
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polymorphisms in ABCB1, the gene which 
encodes p-gp, in cancer patients have been shown 
to play a major role in intracellular concentrations 
of morphine and both metabolites (89). Inhibition 
of p-gp at the time of administration of morphine 
has also been shown to increase the observed 
analgesic effect, confirming p-gp inhibits the 
analgesic effect of morphine (90). It has been 
suggested that other members of the Mdr protein 
family may play roles in the transport of 
morphine’s metabolites (91). 
Research regarding the effect of chronic morphine 
exposure on the BBB is sparse and more 
information is needed to draw definitive 
conclusions. From what has been reported, the 
expression of several different genes in isolated 
microvessels of rats has been shown to change 
following chronic administration of morphine, 
including those in the Mdr family (92). Whole 
brain samples have been shown to have an 
increased expression of p-gp following chronic 
exposure to morphine. However, isolates of brain 
microvessels do not show this increase (92). 
Opioids have been a part of human history since 
the earliest civilizations. Throughout history, 
opioids have been recognized for the ability to 
eliminate pain. Opioids achieve an analgesic 
effect through inhibitory action at mu opioid 
receptors in both the brain and spinal cord. While 
opioids have a positive effect on pain 
management, negative side effects include 
respiratory depression and gastric slowing. 
Chronic opioid use is associated with the 
development of tolerance and dependence. 
Chronic exposure to opioids has become 
increasing prevalent for both clinical and 
recreational users. Patients in this population have 
few options for acute pain management. At the 
BBB, p-gp is an efflux protein known to have 
increased trafficking to the luminal surface of the 
endothelial cells of the BBB during a pain event. 
Understanding the effect of chronic morphine on 
the signal required to initiate p-gp trafficking at 
the BBB in a pain state could lead to a novel 
therapeutic target for improving acute pain 
management in long-term opioid exposed patients. 
MATERIALS AND METHODS  
Reagents: 
EDTA-free complete proteinase inhibitor was 
purchased from Roche (Sigma Aldrich, St. Louis, 
MO). Morphine was acquired from the National 
Institute of Drug Abuse (Bethesda, MD). Tris(2- 
carboxyethyl)phosphine hydrochloride, 20x 
sample reducing agent, 4x sample loading buffer 
and Precision Plus prestained molecular weight 
standards were purchased from Bio-Rad 
(Hercules, CA). Any other chemical was acquired 
through Sigma-Aldrich (St. Louis, MO) unless 
otherwise stated. 
Animals and Treatments: 
All animal protocols used in these studies were 
written in compliance with the written guidelines 
of the National Institutes of Health and approved 
by the University of Arizona Animal Care and 
Use Committee. Results were reported according 
to the ARRIVE guidelines. Female Sprague-
Dawley rats (175-200 g) (Harlan Sprague-Dawley, 
Indianapolis, IN) were cared for using the 
standard conditions in the University of Arizona 
Animal Care Facility. All animals were allowed to 
acclimate for one week before being used in any 
experiment. 
Induction of peripheral inflammatory pain: 
A 0.1 mL injection of either λ-carrageenan (3% in 
0.9% saline) or 0.9% saline was administered to 
the left hind paw of animals 3 hours before 
sacrifice. 
Pump insertion surgery: 
Alzet (Cupertino, CA) osmotic mini-pumps were 
filled to maximum capacity with morphine sulfate 
dissolved in 0.9% saline or 0.9% saline. Morphine 
concentration was appropriate to deliver 5 
mg/kg/day to a rat weighing 200 g. Pumps were 
submerged in 0.9% saline and incubated overnight 
at 37°C. Rats were anesthesitized under 5.0% 
isoflurane in air and maintained at 2.5% isoflurane 
in air. A 1-inch square area at the bottom of the 
scapula was shaved, and an approximately 1.0 cm 
incision was made at this spot through the skin. A 
set of hemostats were used to create a cavity large 
enough to insert the mini-pump under the skin 
with the pumping end of the pump facing away 
from the incision. The incision was closed using 
two surgical staples. Staples remained in the 
animal until sacrifice. Minipumps were weighed 
empty, after filling, after priming, and after 
removal to monitor proper function. Remaining 
volume in the mini pump was determined at 
sacrifice to ensure proper function as well. 
von Frey mechanical sensitivity: 
Two people were present for all behavior studies. 
The up-down method described by Dixon et al. 
was used to establish mechanical allodynia (111). 
Briefly, the rats were placed into the chambers for 
at least 10 minutes to allow them to acclimate 
before any measurements were taken. Rats were 
treated with an acute dose (2.5 mg/kg) of 
morphine in 0.9% saline or 0.9% saline 3 hours 
after injection of 0.1 mL λ-carrageenan or saline 
into the left hind paw as previously described. 
Mechanical sensitivity was tested using von Frey 
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filaments in the assay described by Dixon et al. in 
the ipsilateral paw (111). Mechanical sensitivity 
was measured before surgery, before λ-
carrageenan injection, before morphine injection, 
and 10, 20, 30, 45, 60, 90, 120, and 150 minutes 
after injection of morphine. Pre-surgery and pre-λ-
carrageenan injection values were used to 
determine opioid-induced hyperalgesia. Animals 
that achieved a maximal threshold score following 
exposure were excluded from these calculations 
because the true change in threshold of these 
individuals could not be determined. 
Hargraves’ thermal sensitivity: 
Two people were present for all behavior studies. 
Thermal sensitivity was tested using the method 
described by Hargraves et al. (112). Briefly, rats 
were placed into the chambers for at least 10 
minutes to allow them to acclimate before any 
measurements were taken. The rats were treated 
with an acute dose (2.5 mg/kg) of morphine in 
0.9% saline or 0.9% saline 3 hours after injection 
of 0.1 mL λ-carrageenan or saline into the left 
hind paw. The infrared emitter was placed under 
each foot and turned on. Time to paw withdrawal 
(seconds) was measured using a laboratory timer 
and was started and stopped by the person 
operating the infrared emitter. Thermal sensitivity 
was measured before surgery, before carrageenan 
injection, before morphine injection, and 10, 20, 
30, 45, 60, 90, 120, and 150 minutes after 
injection of morphine. 
Paw Edema: 
Paw edema was measured 3 hours after λ -
carrageenan (or saline) injection, 30 minutes after 
morphine injection, and 150 minutes after 
morphine injection. A Ugo-Basile (Varese, Italy) 
plethysmometer was used to determine the paw 
volume (mL) of both the ipsilateral and 
contralateral hind paws. Rats were restrained, and 
the contralateral paw was measured first followed 
by the ipsilateral paw. Data are expressed as the 
difference between these two measurements. 
Microvessel isolation: 
Cerebral microvessels were isolated as previously 
described (84). Briefly, rats were anesthetized, 
decapitated, and the brains removed. Brains were 
minced and homogenized using a Potter-Elvjehm 
homogenizer. Samples were layered over 30% 
Ficol and centrifuged (20 min at 5800 x g at 4°C) 
to remove the majority of the lipids. The vessels 
found in the pellet were resuspended in buffer and 
filtered using a series of nylon mesh filters. These 
limited the remaining vessels to pieces which 
were between 300 μm and 40 μm. Samples were 
frozen at -20°C or used for a subsequent 
biochemical analysis. 
Nuclear/cytosolic protein analysis: 
Animals of like treatment were pooled to create 
samples consisting of 3 independent rats coming 
from different cages. Nuclei were isolated using 
the instructions provided with the Thermo 
Scientific NE-PER Nuclear and Cytoplasmic 
Extraction Kit (ThermoFisher Scientific, 
Rockford, IL). This includes Cytoplasmic 
Extraction Reagent I (CER I), Cytoplasmic 
Extraction Reagent II (CER II) and Nuclear 
Extraction Reagent (NER). Briefly, microvessels 
isolated using the previously described technique 
were suspended in an appropriate volume of CER 
I. These were vortexed vigorously for 15 seconds 
and left to incubate on ice for 10 minutes. An 
appropriate volume of CER II was then added to 
the sample. This sample was then vortexed for 5 
seconds and left to incubate on ice for 1 minute. 
Vortexing again for 5 seconds, the sample was 
then centrifuged at 16,000 x g for 5 minutes. The 
supernatant represented the cytoplasmic extract 
and was saved. The pellet was suspended in an 
appropriate volume of NER. The sample was 
vortexed for 15 seconds every 10 minutes for 40 
minutes as the sample incubated on ice. The 
sample was then centrifuged for 10 minutes at 
16,000 x g. The supernatant contained the nuclear 
extract. 
Western Blot and Quantification: 
Equal concentrations of nuclear and cytosolic 
protein were separated via SDS-PAGE gel 
electrophoresis loaded onto Criterion TGX 4-20% 
gels (Bio-Rad). Proteins were detected and 
quantified using antibodies to MDR1 (sc8313) and 
nucleoporin p62 (sc25523) from Santa Cruz 
Biotechnology (Santa Cruz Biotechnology, Dallas, 
TX). An HRP-linked anti-rabbit secondary (GE 
Healthcare, Piscataway, NJ) was used for the 
detection of these antibodies. Proteins were 
measured by chemiluminescence using the Clarity 
bioluminescence kit (Bio-Rad) and imaged on a 
ChemiDoc System (Bio-Rad). Bands were 
quantitated by importing the image into Image 
Lab (Bio-Rad) and exported them from the 
program. The bands were quantified following 
removal of background signal using the 
algorithms in FIJI (113). These images were 
cropped and the contrast and brightness adjusted 
for the entire cropped portion before constructing 
the figure. 
Statistics: 
Difference between means was tested using the 
Student’s t-test using the algorithms in Microsoft 
Excel (Microsoft, Redmond, WA). 
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RESULTS 
Osmotic minipumps can be used to establish 
tolerance to morphine 
The long-term goal in this line of experimentation 
is to establish a mechanism for post-translational 
regulation of P-gp and to apply this mechanism to 
more effective pain therapies by improving opioid 
delivery to the brain. In previous experiments, 
peripheral inflammatory pain (PIP) has been 
shown to increase PIP mediated p-gp trafficking at 
the (86). Experimentation by Zong and Pollack 
has shown that the chronic administration of p-gp 
substrates is sufficient to induce changes in whole 
brain p-gp (114).  
Tests using the up-down method of von Frey 
mechanical sensitivity demonstrated that 
morphine exposure from osmotic minipumps 
induced opioid-induced hyperalgesia (OIH) (Fig 
1) (111). OIH was identified by a marked increase 
in mechanical sensitivity between thresholds 
determined before the pump insertion surgery and 
after six days of morphine exposure. Animals that 
received a morphine pump had a 50% reduction in 
mechanical thresholds after morphine exposure 
(p<0.001). Post-exposure thresholds for animals 
treated with morphine were significantly lower 
than the post-exposure values for animals that 
were treated with the saline control (p<0.001). 
Animals not exposed to morphine showed no 
significant decrease in mechanical thresholds 
following exposure. There was no significant 
difference in pre-surgery mechanical sensitivity 
between the two groups. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Six day exposure to morphine from 
osmotic mini-pump causes opioid-induced 
hyperalgesia in female rats. Mechanical allodynia 
was measured in female Sprague-Dawley rats 
before receiving surgery to insert an osmotic mini-
pump and after six days exposure to the pump. 
Animals received morphine (5 mg/kg/day) in 0.9% 
saline (MOR) or 0.9% saline (SAL) for six days 
before testing again. Values are mean + SEM (n=9) 
Lines indicate compared values. *** denotes 
significantly different (p<0.001). 
Osmotic minipumps can be used to establish 
tolerance to morphine (mechanical allodynia) 
The von Frey up-down assay was used with the 
previously established model of PIP induced by λ -
carrageenan injection in the rat hind paw to 
investigate morphine tolerance (111). In morphine 
tolerance, the reduction of mechanical allodynia 
by an acute dose of morphine is reduced or 
eliminated entirely following chronic exposure, 
such as that from the mini-pumps. Intraperitoneal 
injection of 2.5 mg/kg morphine was used for 
anti-nociception in these experiments. 
By measuring the paw withdrawal threshold in the 
inflamed hind paw over a time course of 2.5 
hours, rats pre-exposed to morphine then given the 
acute dose were indistinguishable from those that 
received no acute morphine at all (Fig 2A). 
Mechanical allodynia was determined to be 
reduced by an acute dose of morphine in animals 
with no pre-exposure to morphine. Animals that 
did not receive an acute dose of morphine did not 
have a change in sensitivity in the ipsilateral paw. 
The anti-nociceptive effect was seen from 20 to 60 
minutes in these animals and the area under the 
curve for this period was quantified for both 
groups that received an acute dose of morphine 
(Fig 2B). A comparison of the determined area 
under the curve for these groups showed a 
significantly larger area for the morphine naïve 
animals (p<0.0001). Animals with no injection of 
λ-carrageenan tended to have a lower mechanical 
threshold when exposed to morphine for six days 
(Fig 3). 
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Figure 2.Prolonged morphine exposure eliminates the anti-nociceptive effect of acute morphine 
administration on mechanical sensitivity. (A) Mechanical paw withdrawal threshold was determined by the 
von Frey mechanical sensitivity test in rats exposed to 5 mg/kg/day of morphine or saline for 6 days, then 
treated with an acute dose (2.5 mg/kg) of morphine or saline 3 hours after injection of λ -carrageenan into the 
left hind paw. The symbols mean: SCS: Saline Osmotic mini-pump (24μL/day)/ -carrageenan hind paw 
injection (0.1 mL)/ Saline intraperitoneal injection (1mL/kg);SCM: Saline Osmotic mini-pump (24μL/day)/ -
carrageenan hind paw injection (0.1 mL)/ Morphine intraperitoneal injection (1mL/kg) (2.5mg/kg);MCS: 
Morphine Osmotic mini-pump (24μL/day) (5mg/kg/day)/ -carrageenan hind paw injection (0.1 mL)/ Saline 
intraperitoneal injection (1mL/kg);MCM: Morphine Osmotic mini-pump (24μL/day) (5mg/kg/day)/ -
carrageenan hind paw injection (0.1 mL)/ Morphine intraperitoneal injection (1mL/kg) (2.5mg/kg). Values are  
the mean +/- SEM (n=8). (B) The area under the curve for the animals treated with SCM and MCM during the 
peak observed morphine effect (between 20 minutes and 60 minutes). Values are the mean + SEM (n=8). *** 
denotes significantly different (p<0.0001) 
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Figure 3. Chronic morphine administration 
tends to reduces mechanical sensitivity 
thresholds determined by the von Frey test in 
the ipsilateral paw. The symbols mean: 
SSS: Saline Osmotic mini-pump 
(24μL/day)/ saline hind paw injection (0.1 mL)/ 
Saline intraperitoneal injection (1mL/kg); SSM: 
Saline Osmotic mini-pump (24μL/day)/ saline 
hind paw injection (0.1 mL)/ Morphine 
intraperitoneal injection (1mL/kg) 
(2.5mg/kg);MSS: Morphine Osmotic mini-pump 
(24μL/day) (5mg/kg/day)/ saline hind 
paw injection (0.1 mL)/ Saline intraperitoneal 
injection (1mL/kg);MSM: Morphine Osmotic 
mini-pump (24μL/day) (5mg/kg/day)/ saline hind 
paw injection (0.1 mL)/ Morphine intraperitoneal 
injection (1mL/kg) (2.5mg/kg). Values are mean 
+/- SEM (n=8). 
Osmotic minipumps can be used to establish 
tolerance to morphine (thermal sensitivity) 
The inability of an acute dose of morphine to 
reduce thermal sensitivity in animals previously 
exposed to morphine is another marker of 
acquired morphine tolerance. Using the same time 
course as the von Frey experiment, the Hargreaves 
method for determining thermal sensitivity was 
implemented to measure sensitivity (112). Paw 
withdrawal latency (s) was used as the measure 
for each point. Rats that had been pre-exposed to 
morphine had a greatly reduced anti-nociceptive 
response to morphine (Fig 4A). Morphine naïve 
animals had a distinct period in which thermal 
sensitivity was reduced. Animals that did not 
receive an acute dose of morphine did not have a 
change in sensitivity in the ipsilateral paw. For 
this experiment, an anti-nociceptive effect was 
seen from 30 to 60 minutes in the animals with no 
pre-exposure to morphine. The area under the 
curve was larger for the animals with no pre-
exposure to morphine (p<0.01) (Fig 4B). Animals 
with no injection of λ-carrageenan showed no 
change over the time course (Fig 5). 
Measurements in the contralateral paw showed no 
changes regardless of treatment. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Prolonged morphine exposure 
eliminates the anti-nociceptive effect of acute 
morphine administration on thermal 
sensitivity. (A) Thermal paw withdrawal 
threshold was determined by the Hargraves 
thermal sensitivity test in the ipsilateral paw of 
rats exposed to 5 mg/kg/day of morphine or saline 
for 6 days, then treated with an acute dose (2.5 
mg/kg) of morphine or saline 3 hours after 
injection of λ-carrageenan into the left hind paw 
(n=9). The symbols mean: SCS: Saline Osmotic 
mini-pump (24μL/day)/ -carrageenan hind paw 
injection (0.1 mL)/ Saline intraperitoneal injection 
(1mL/kg);SCM: Saline Osmotic mini-pump 
(24μL/day)/ -carrageenan hind paw injection 
(0.1 mL)/ Morphine intraperitoneal injection 
(1mL/kg) (2.5mg/kg);MCS: Morphine Osmotic 
mini-pump (24μL/day) (5mg/kg/day)/ -
carrageenan hind paw injection (0.1 mL)/ Saline 
intraperitoneal injection (1mL/kg);MCM: 
Morphine Osmotic mini-pump (24μL/day) 
(5mg/kg/day)/ -carrageenan hind paw injection 
(0.1 mL)/ Morphine intraperitoneal injection 
(1mL/kg) (2.5mg/kg). Values are the mean +/- 
SEM (n=9). (B) The area under the curve for the 
animals treated with SCM and MCM during the 
peak observed morphine effect (between 30 
minutes and 60 minutes).Values are mean + SEM 
(n=9). * denotes significantly different (p=0.007). 
Chronic morphine exposure does not affect paw 
edema in a λ-carrageenan induced model of 
peripheral inflammatory pain 
While previous studies have shown that the pain 
component of the PIP is the important component 
for the effect on the BBB, the inflammation and 
edema may play an important role in the 
magnitude of the pain. To be sure long-term 
       10  
43 
Asian Journal of Multidisciplinary Studies, 5(10) October, 2017 
 
  
  
 
 
 
morphine exposure did not affect the swelling in 
the paw, the volume of both feet was compared as 
a way to determine paw edema. At 3 hours post 
injection of λ-carrageenan, the injected paw was  
shown to be increased by 0.79 +/- 0.06 and 0.80 
+/- 0.05 mL relative to the other hind paw in the 
saline exposed and morphine-exposed animals 
used for the von Frey experiment, respectively 
(Fig 6A). At 3 hours post injection of λ -
carrageenan, the injected paw was shown to be 
increased by 0.96 +/- 0.03 and 0.87 +/- 0.06 mL 
relative to the other hind paw in the saline 
exposed and morphine-exposed animals used for 
the Hargreaves experiment, respectively (Fig 5B). 
Animals that received a paw injection of saline did 
not have a significant difference in paw volume, 
regardless of treatment demonstrating that chronic 
morphine exposure has no effect on paw edema. 
 
 
 
 
 
 
 
 
 
Figure 5. Chronic morphine exposure has no effect on hind paw edema following λ-carrageenan 
exposure paw edema measurements in the animals tested for mechanical allodynia (A) or thermal 
sensitivity (B). The symbols mean: SS: Saline mini-osmotic pump/ Saline hind paw injection (100μL); SC: 
Saline mini-osmotic pump/ -carrageenan hind paw injection (100μL); MS: Morphine(5mg/kg/day) mini-
osmotic pump/ Saline hind paw injection (100μL); MC: Morphine(5mg/kg/day) mini-osmotic pump/ -
carrageenan hind paw injection (100μL). Values are the mean + SEM (A n=16, B n=18). *** denotes 
significantly different (p<0.0001) 
PIP mediated trafficking of P-gp leaving the nucleus is increased by long term opioid exposure  
PIP is sufficient to induce trafficking of p-gp away from nuclear reservoirs (86). Using a nuclear protein 
isolation assay, protein from the cytoplasm and nuclear membrane of endothelial cells from isolated 
microvessels was isolated. Nucleoporin acted as a control for the purity of the nuclear fractions (Fig 7A). A 
six-day morphine exposure did not change the nuclear p-gp (Fig 7B). Animals exposed to morphine showed a 
46% decrease in nuclear p-gp when given a PIP stimulus (Fig 7C). Animals with a saline pump showed a 24% 
reduction in nuclear p-gp when exposed to PIP (Fig 6C). 
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Figure 6. Chronic morphine exposure increases 
trafficking of p-glycoprotein away from the 
nucleus after peripheral inflammatory pain. 
(A) Representative immunoblot indicating the p-
gp and nucleoporin in the nuclear and cyctosolic 
isolates. (B) P-gp expresion normalized to 
nucleoporin in the nuclear fractions. Values are 
the mean + SEM (n=3 pools of 3 rats each) (C) 
Ratio of nuclear p-gp normalized to nulcoporin in 
CAR/SAL injected animals as a measure of p-gp 
trafficking. Values are the mean + SEM (n=3). * 
denotes significantly differnent from control 
(saline) (p<0.05). The symbols mean: SAL/SAL 
represents animals with an osmotic mini-pump 
filled with 0.9% saline and a 0.9% saline hind paw 
injection.MOR/SAL represents animals with an 
osmotic mini-pump filled with morphine (5 
mg/kg./day) in 0.9% saline and a 0.9% saline hind 
paw injection. 
DISCUSSION 
Long-term opioid exposure is sufficient to induce 
a 2-fold increase in peripheral inflammatory pain 
(PIP) mediated trafficking of p-glycoprotein (p-
gp) away from the nucleus in rat brain endothelial 
cells. This presents a possible role of p-gp in the 
clinical challenges associated with decreased 
opioid efficacy in long-term opioid patients in 
need of acute pain management (2,3). Utilizing 
the previously established model of PIP via 
injection of λ-carrageenan and an observation that 
PIP induces p-gp trafficking from nuclear 
reservoirs to the plasma membrane (86), we tested 
whether there could be a relationship between p-
gp trafficking and clinical challenges of acute pain 
management in long-term opioid patients. 
This experimental approach required the 
establishment of a model of long-term opioid 
exposure and opioid tolerance in female rats. The 
subdermal osmotic mini-pump method of delivery 
allowed us to deliver a consistent dose of opioids 
(115). These behavior data suggest this delivery 
method was sufficient to induce tolerance to the 
mechanical allodynia and thermal sensitivity 
mediating effects of morphine after an acute pain 
stimulus. These data also showed an increase in 
baseline mechanical allodynia but not thermal 
sensitivity. The up-down method of analyzing von 
Frey filament data has been shown to be an 
effective way to detect mechanical allodynia in 
rodents when analyzed with the Dixon statistic 
(111,116). A 50% reduction in mechanical pain 
threshold compared to both pre-surgery values and 
animals who received a control pump 
demonstrates that using this method; morphine 
exposure via these osmotic pumps caused opioid-
induced hyperalgesia (OIH) to occur in female 
rats. OIH to mechanical stimuli is an observed 
phenomenon that is particularly associated with 
the effects of long-term opioid exposure in female 
rats, making a particularly good marker for 
tolerance in these experiments (117). Baseline 
allodynia was observed 3 hours post injection of 
λ-carrageenan in the treated hind paw to the same 
extent in all animals, regardless of which pre-
treatment the animal received. 
P-gp trafficking from the nuclear membrane to the 
luminal membrane of endothelial cells making up 
the BBB presents a major problem for delivery of 
opioids into the CNS in the presence of acute pain. 
This trafficking effect is amplified by the 
persistent presence of a p-gp substrate such as 
morphine. A clinically relevant example of this is 
the challenges associated with post-surgical pain 
management in patients being treated long-term 
with opioids. Pain management in these patients is 
particularly difficult and causes increased 
recovery times and reduced patient satisfaction. 
The mechanism by which this trafficking occurs is 
currently unknown, but the characterization of this 
mechanism is a promising therapeutic target. 
Conclusions and Future Directions  
This study demonstrated that long-term exposure 
to morphine causes an increase in the p-
glycoprotein (p-gp) trafficking response induced 
by peripheral inflammatory pain (PIP) at the 
blood-brain barrier (BBB). Pain induced 
trafficking of p-gp decreases the efficacy of 
morphine (6). Pain decreasing the efficacy of the 
analgesic morphine is a clear clinical problem. P-
gp trafficking at the BBB impacts delivery to the 
central nervous system (CNS), but not to other 
peripheral targets. Peripheral mu opioid receptors 
mediate many of the side effects associated with 
opioids such as respiratory depression and gastric 
slowing leading to constipation. In a clinical 
setting, morphine is administered via self-
administration systems called Patient Controlled 
Analgesia systems (2). Because this is controlled 
by the patient in an attempt to manage pain, the 
patient will continue to increase the dose of the 
analgesic, but because of a decreased delivery to 
the CNS caused by p-gp mediated trafficking at 
the BBB, peripheral side effects may become 
more severe. This study shows this could be more 
severe for patients with a history of long-term 
opioid use. This observation suggests the 
increased PIP-mediated trafficking of p-gp may be 
a potential factor in the challenge of managing 
acute pain in opioid tolerant patients. 
Characterizing this mechanism could lead to more 
effective post-surgical pain management in these 
patients. Altering p-gp trafficking would allow 
opioid tolerant patients to manage post-surgical 
pain more effectively. Improved pain management 
means improved recovery from injury and less 
time taken from the physician to manage pain.. 
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Surgery is an increasingly common solution to 
attempt to correct chronic pain, seeing application 
in hernia pain, groin pain and neck pain (125–127). 
Patients already receiving chronic opioid therapy 
for chronic pain that desire to seek a surgical 
approach to managing pain are a group of particular 
interest. Investigations into the role of p-gp and the 
BBB could lead to more effective strategies for 
managing post-surgical pain in this growing 
population of chronic pain patients receiving long-
term opioid therapy. The pain associated with the 
recovery from the mini pump insertion surgery 
performed on these rats makes this model a 
potential means of investigating this problem. 
Because there was no control for the chronic post-
surgical pain included in this study, further 
investigation of the effect of chronic pain is 
needed. 
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